Morten Rostrup

• Olsen, Eirik; Søraas, Camilla Lund; Schmieder, Roland E; Jamerson, Kenneth; MacDonald, Thomas M & Mancia, Giuseppe [Show all 17 contributors for this article] (2025). Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients. American Journal of Hypertension. ISSN 0895-7061. 38(12), p. 1106–1119. doi: 10.1093/ajh/hpaf093. Full text in Research Archive Show summary

  BACKGROUND Protecting the kidneys by lowering systolic blood pressure (SBP) in hypertensive patients is not unequivocally settled. We tested the hypothesis that achieving lower average SBP in middle-aged and older high-risk hypertensive patients with and without type-2 diabetes mellitus through several years would clarify kidney protection. METHODS We analyzed patients 50–80 years with no cardiovascular events during the first 6 months of drug up-titration after randomization to valsartan or amlodipine, and with 3 or more visits onwards with standardized BP measurements. Adjusted Cox analyzes compared worsened kidney function defined as a 50% rise in se-creatinine on a minimum of two occasions at least 4 weeks apart or end-stage kidney disease (ESKD) in achieved SBP quartiles and in patients who achieved SBP < 130 and 130–139 mmHg with patients whose SBP remained ≥140 mmHg. RESULTS A total of 13,803 patients were investigated of whom 4,655 had DM. Patients with DM had less worsened kidney function at SBP 130–139 mmHg (HR = 0.524, 95% CIs 0.375–0.733, n = 1849, P < 0.001) and at SBP < 130 mmHg (HR = 0.538, CIs 0.316-0.915, n = 674, P = 0.022) compared with patients at ≥ 140 mmHg. They also had less ESKD at SBP 130-139 mmHg (HR = 0.442, CIs 0.196–1.000, P = 0.050) with a similar trend at SBP < 130 mmHg and in quartile analysis with only 1 ESKD in the lowest quartile. Findings in patients without DM (n = 9,148) were similar to DM. CONCLUSIONS In high-risk hypertensive patients aged 50–80 years, with and without DM, targeting SBP of 130–139 mmHg confers kidney protection with possible further benefit at the lower target of SBP < 130 mmHg. Clinical trials registration Trial Number NCT06395194, www.clinicaltrials.gov.

• Watland, Solbjørg; Nes, Lise Solberg; Ekeberg, Øivind; Rostrup, Morten; Hanson, Elizabeth & Ekstedt, Mirjam [Show all 8 contributors for this article] (2025). Effects of The Caregiver Pathway intervention on symptoms of post-intensive care syndrome among family caregivers to critically ill patients: long-term results from a randomized controlled trial. Intensive Care Medicine. ISSN 0342-4642. 51(11), p. 2042–2053. doi: 10.1007/s00134-025-08139-x. Full text in Research Archive Show summary

  Purpose: A long-term evaluation of The Caregiver Pathway, a model to follow up family caregivers on Post-intensive Care Symptoms among Family (PICS-F). Methods: A single-center non-blinded randomized controlled trial including 196 family caregivers to critically ill patients randomized to intervention (n = 101) or control group (n = 95). The Caregiver Pathway intervention consists of: (1) a digital assessment followed by a conversation with a nurse in the first days at the ICU, (2) a supportive card when leaving the ICU, (3) an offer to receive a phone call following patient transfer to a step-down unit, and (4) a followup conversation within 3 months after discharge. Outcome measures were collected at 6 and 12 months, including symptoms of post-traumatic stress disorder (PTSD), anxiety, depression, Health-related Quality of Life (HRQoL), hope,and self-efficacy. Results: The Caregiver Pathway was associated with a significant effect for symptoms of PTSD after 6 months compared with controls, mean IES-R score: 25.8 [95% CI 21.9–29.7] versus 30.9 [95% CI 26.7–35.0], p = 0.009, and a trend toward an effect after 12 months: IES-R score: 25.0 [95% CI 21.3–28.7] versus 28.4 [95% CI 24.1–32.7], p = 0.057. Subgroup analyses at 12 months showed a significant intervention effect among family caregivers of patients who survived compared to controls for PTSD, IES-R score: 19.8 [95% CI 15.3–24.2] versus 29.1 [95% CI 23.5–34.6], p = 0.001, and anxiety, HADS-A score: 4.3 [95% CI 3.1–5.4] versus 6.8 [95% CI 5.2–8.4], p = 0.003. Conclusions: The Caregiver Pathway has the potential to reduce the symptoms of PICS-F, especially among family caregivers whose patient has survived.

• Aarskog, Nikolai Ravn; Bjørsrud, Hanna Othilie Lindvig; Holten, Aleksander Rygh; Watne, Leiv Otto; Neerland, Bjørn Erik & Rostrup, Morten (2025). Ventilatory response and delirium risk in hospitalised patients with acute hypoxia due to COVID-19. Scientific Reports. 15. doi: 10.1038/s41598-025-13016-0. Full text in Research Archive Show summary

  Mountaineers with a high ventilatory response to hypoxia experience greater cognitive impairment at high altitude, possibly because hyperventilation causes hypocapnia, cerebral vasoconstriction and ultimately cerebral ischaemia. We hypothesised that a high ventilatory response, and consequently a lower arterial partial pressure of carbon dioxide (PaCO2), could increase the risk of delirium in hospitalised patients with acute hypoxia. To test our hypothesis, we conducted a cohort study in which PaCO2 and arterial oxygen saturation were measured upon hospital admission in 126 patients with COVID-19. After adjusting for oxygen saturation, we found that a lower PaCO2 was associated with a higher risk of delirium during hospital admission (risk ratio 1.67 [95% confidence interval 1.09–2.54] per 1 kilopascal reduction, P = 0.017). The association remained statistically significant after adjusting for other well-established risk factors for delirium. This finding supports our hypothesis that a high hypoxic ventilatory response increases the risk of delirium in patients with acute hypoxia.

• Olsen, Eirik; Halvorsen, Lene Vernås; Rognstad, Stine; Aune, Arleen; Brobak, Karl Marius & Bergland, Ola Undrum [Show all 17 contributors for this article] (2025). Characteristics of adherent and non-adherent patients with hypertension in a Norwegian cross-sectional study. Exploration of Medicine. 6. doi: 10.37349/emed.2025.1001279. Full text in Research Archive
• Olsen, Erik; Jamerson, Kenneth; Schmieder, Roland E.; Søraas, Camilla Lund; Mariampillai, Julian Eek & Mancia, Giuseppe [Show all 17 contributors for this article] (2024). Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial. European journal of internal medicine. ISSN 0953-6205. doi: 10.1016/j.ejim.2024.12.021. Full text in Research Archive Show summary

  Background There is a paucity of data investigating the impact of antihypertensive drug classes and blood pressure (BP) treatment targets on the incidence of end-stage kidney disease (ESKD). In patients with high-risk hypertension aged 50–80 years or above, we aimed to, 1) compare effects of valsartan, an angiotensin receptor blocker, with amlodipine, a calcium channel blocker and, 2) assess the effect of achieving systolic BP <135 vs ≥135 mmHg on the ESKD incidence. Methods The VALUE Trial was a multicenter prospective double-blinded randomized clinical trial in patients with essential hypertension and high cardiovascular risk including known coronary disease, left ventricular hypertrophy and previous stroke, in which ESKD was a secondary endpoint defined as progression to kidney transplant and/or dialysis. Patients were randomized to either valsartan or amlodipine, with other anti-hypertensive medications as add-on if needed to reach the systolic BP target of <140 mmHg. Cox proportional hazards ratio (HR) was used to compare different treatment groups and achieved systolic BP <135 with ≥135 mmHg, during 3–6 years of follow-up. Results 15,245 patients were randomized and followed until 63,631 patient-years with only 90 patients lost to follow-up. The primary outcome, a composite of cardiac morbidity and mortality, was neutral between valsartan and amlodipine. On valsartan 47 patients (0.61 %) and on amlodipine 50 patients (0.66 %) developed ESKD (HR=1.02, 95 % CI 0.68–1.52, p =0.94). Achieved SBP <135 mmHg was strongly related to less ESKD (n =9/5036 patients, 0.2 %) compared with achieved SBP ≥135 mmHg (n =73/8766 patients, 0.8 %) (HR=0.28, CI 0.14–0.58, p <0.001). Conclusions In hypertensive patients with a high cardiovascular risk, valsartan and amlodipine have a similar impact on the incidence of end-stage kidney disease. Achieving SBP <135 mmHg, averaging 128.8/77.3 mmHg, is highly efficacious in kidney protection.

• Aarskog, Nikolai Ravn; Hallem, Ronja; Godhavn, Jakob Strand & Rostrup, Morten (2024). Time-Dependent Changes in Pulmonary Turnover of Thrombocytes during Critical COVID-19. Critical Care Explorations. 6(7), p. e1128–e1128. doi: 10.1097/CCE.0000000000001128. Full text in Research Archive
• Halvorsen, Lene Vernås; Søraas, Camilla Lund; Larstorp, Anne Cecilie Kjeldsen; Hjørnholm, Ulla; Kjær, Vibeke Norheim & Liestøl, Knut [Show all 21 contributors for this article] (2024). Effect of Therapeutic Drug Monitoring on Adherence and Blood Pressure: A Multicenter Randomized Clinical Trial. American Journal of Hypertension. ISSN 0895-7061. 37(10), p. 826–836. doi: 10.1093/ajh/hpae059. Full text in Research Archive Show summary

  BACKGROUND Drug concentration in blood or urine is an acknowledged method to detect nonadherence. Observational studies suggest that informing patients about low or absent serum drug levels improves blood pressure (BP). We performed a multicenter randomized clinical trial to test the hypothesis that therapeutic drug monitoring (TDM) could improve drug adherence and BP in patients with uncontrolled hypertension (HT). METHODS Patients were ≥18 years on stable treatment with at least 2 antihypertensive agents. We planned to randomize 80 nonadherent patients with a systolic daytime ambulatory BP ≥135 mm Hg to TDM intervention or not. The control group and the study personnel who measured BP remained uninformed about serum drug measurements throughout. All patients and physicians were blinded for BPs. Lifestyle advice and detailed information on the disease process and the importance of BP treatment were given to both groups. RESULTS From 2017 to 2022, we randomized 46 diagnosed nonadherent from a total of 606 patients with uncontrolled HT. The TDM group had a 6.7 (±14.5) mm Hg reduction from 147.9 (±10.3) to 141.1 (±14.1) mm Hg, and the control group experienced a 7.3 (±13.2) mm Hg reduction from 147.1 (±9.2) to 139.1 (±17.4) mm Hg, P = 0.9 between groups. Adherence improved in both groups, 73% in the TDM group and 59% in the control group became adherent at 3 months, P = 0.51. CONCLUSIONS In our prospective multicenter clinical trial of uncontrolled and nonadherent hypertensive patients, we found no additional effect of TDM on BP and drug adherence compared with standard care.

• Watland, Solbjørg; Nes, Lise Solberg; Ekeberg, Øivind; Rostrup, Morten; Hanson, Elizabeth & Ekstedt, Mirjam [Show all 9 contributors for this article] (2024). The Caregiver Pathway Intervention Can Contribute to Reduced Post-Intensive Care Syndrome Among Family Caregivers of ICU Survivors: A Randomized Controlled Trial. Critical Care Medicine. ISSN 0090-3493. 53(3), p. 1–12. doi: 10.1097/CCM.0000000000006546. Full text in Research Archive Show summary

  OBJECTIVES: Explore short-term effects of “The Caregiver Pathway,” an inter- vention for family caregiver follow-up, on Post-Intensive Care Syndrome symp- toms among families (PICS-F). DESIGN: A randomized controlled trial. SETTING: A medical ICU at a Norwegian University Hospital. PARTICIPANTS: One hundred ninety-six family caregivers of critically ill patients randomized to an intervention (n = 101) or control group (n = 95). INTERVENTIONS: “The Caregiver Pathway” four-step model offers individual and structured follow-up, including: 1) mapping family caregivers’ needs and con- cerns with an assessment tool followed by a conversation with an ICU nurse within the first days at the ICU, 2) a supportive card when leaving the ICU, 3) offer for the family caregivers to receive a phone call after ICU patient discharge, and 4) a follow-up conversation within 3 months. MEASUREMENTS AND MAIN RESULTS: Data were collected at baseline and after 3 months and analyzed using linear regression. No significant effects were detected when comparing all participants completing 3-month outcome measurements (n = 144). A subgroups analysis stratified on patient survival, how- ever, showed statistically significant effect for family caregivers of patients surviv- ing the ICU stay receiving the intervention compared with controls. Caregivers of surviving patients reported improved symptoms related to post-traumatic stress disorder, measured by Impact of Event Scale-Revised (B = –8.2 [95% CI, –14.2 to –2.2]; p = 0.008), anxiety (B = –2.2 [95% CI, –4.0 to –0.5]; p = 0.014), and depression (B = –1.5 [95% CI, –2.9 to –0.1]; p = 0.035); measured by the Hospital Anxiety and Depression Scale, subscore physical functioning in health- related quality of life (B = 9.7 [95% CI, 0.3–19.0]; p = 0.043); measured by Short Form 12-Item Health Survey; and hope (B = 2.4 [95% CI, 0.4–4.3]; p = 0.017) and measured by the Herth Hope Index. At 3-month, the model did not appear to improve the outcomes for family caregivers of nonsurviving patients. CONCLUSIONS: “The Caregiver Pathway” intervention was associated with reduced symptoms of PICS-F in family caregivers of surviving ICU patients com- pared with controls.

• Heimark, Sondre; Mehlum, Maria Hollund; Mancia, Giuseppe; Søraas, Camilla Lund; Liestøl, Knut & Wachtell, Kristian [Show all 12 contributors for this article] (2023). Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg. Hypertension. ISSN 0194-911X. 80(8), p. 1739–1748. doi: 10.1161/HYPERTENSIONAHA.123.21454. Full text in Research Archive
• Halvorsen, Lene Vernås; Bergland, Ola Undrum; Søraas, Camilla Lund; Larstorp, Anne Cecilie Kjeldsen; Hjørnholm, Ulla & Kjær, Vibeke Norheim [Show all 14 contributors for this article] (2022). Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7-Year Follow-Up of Patients Considered Adherent by Directly Observed Therapy. Journal of the American Heart Association (JAHA). 11(18). doi: 10.1161/JAHA.121.025879. Full text in Research Archive Show summary

  Background Measurement of serum concentrations of drugs is a novelty found useful in detecting poor drug adherence in patients taking ≥2 antihypertensive agents. Regarding patients with treatment‐resistant hypertension, we previously based our assessment on directly observed therapy. The present study aimed to investigate whether serum drug measurements in patients with resistant hypertension offer additional information regarding drug adherence, beyond that of initial assessment with directly observed therapy. Methods and Results Nineteen patients assumed to have true treatment‐resistant hypertension and adherence to antihypertensive drugs based on directly observed therapy were investigated repeatedly through 7 years. Serum concentrations of antihypertensive drugs were measured by ultra‐high‐performance liquid chromatography–tandem mass spectrometry from blood samples taken at baseline, 6‐month, 3‐year, and 7‐year visits. Cytochrome P450 polymorphisms, self‐reported adherence and beliefs about medicine were performed as supplement investigations. Seven patients (37%) were redefined as nonadherent based on their serum concentrations during follow‐up. All patients reported high adherence to medications. Nonadherent patients expressed lower necessity and higher concerns regarding intake of antihypertensive medication (P=0.003). Cytochrome P450 polymorphisms affecting metabolism of antihypertensive drugs were found in 16 patients (84%), 21% were poor metabolizers, and none were ultra‐rapid metabolizers. Six of 7 patients redefined as nonadherent had cytochrome P450 polymorphisms, however, not explaining the low serum drug concentrations measured in these patients. Conclusions Our data suggest that repeated measurements of serum concentrations of antihypertensive drugs revealed nonadherence in one‐third of patients previously evaluated as adherent and treatment resistant by directly observed therapy, thereby improving the accuracy of adherence evaluation. Registration URL: https://www.clinicaltrials.gov; unique identifier: NCT01673516.

• Udjus, Camilla; Sjaastad, Ivar; Hjørnholm, Ulla; Tunestveit, Torbjørn Kinne; Hoffmann, Pavel & Hinojosa, Alexis [Show all 11 contributors for this article] (2022). Extreme altitude induces divergent mass reduction of right and left ventricle in mountain climbers. Physiological Reports. 10(3). doi: 10.14814/phy2.15184. Full text in Research Archive Show summary

  Mountain climbing at high altitude implies exposure to low levels of oxygen, low temperature, wind, physical and psychological stress, and nutritional insufficiencies. We examined whether right ventricular (RV) and left ventricular (LV) myocardial masses were reversibly altered by exposure to extreme altitude. Magnetic resonance imaging and echocardiography of the heart, dual x-ray absorptiometry scan of body composition, and blood samples were obtained from ten mountain climbers before departure to Mount Everest or Dhaulagiri (baseline), 13.5 ± 1.5 days after peaking the mountain (post-hypoxia), and six weeks and six months after expeditions exceeding 8000 meters above sea level. RV mass was unaltered after extreme altitude, in contrast to a reduction in LV mass by 11.8 ± 3.4 g post-hypoxia (p = 0.001). The reduction in LV mass correlated with a reduction in skeletal muscle mass. After six weeks, LV myocardial mass was restored to baseline values. Extreme altitude induced a reduction in LV end-diastolic volume (20.8 ± 7.7 ml, p = 0.011) and reduced E’, indicating diastolic dysfunction, which were restored after six weeks follow-up. Elevated circulating interleukin-18 after extreme altitude compared to follow-up levels, might have contributed to reduced muscle mass and diastolic dysfunction. In conclusion, the mass of the RV, possibly exposed to elevated afterload, was not changed after extreme altitude, whereas LV mass was reduced. The reduction in LV mass correlated with reduced skeletal muscle mass, indicating a common denominator, and elevated circulating interleukin-18 might be a mechanism for reduced muscle mass after extreme altitude.

• Bergland, Ola Undrum; Halvorsen, Lene Vernås; Søraas, Camilla Lund; Hjørnholm, Ulla; Kjær, Vibeke Norheim & Rognstad, Stine [Show all 22 contributors for this article] (2021). Detection of Nonadherence to Antihypertensive Treatment by Measurements of Serum Drug Concentrations. Hypertension. ISSN 0194-911X. 78(3), p. 617–628. doi: 10.1161/HYPERTENSIONAHA.121.17514. Full text in Research Archive Show summary

  Nonadherence to drugs is a challenge in hypertension treatment. We aimed to assess the prevalence of nonadherence by serum drug concentrations compared with 2 indirect methods and relate to the prescribed drug regimens in a nationwide multicenter study. Five hundred fifty patients with hypertension using ≥2 antihypertensive agents participated. We measured concentrations of 23 antihypertensive drugs using ultra high performance liquid chromatography tandem mass-spectrometry and compared with patients’ self-reports and investigators’ assessment based on structured interview. We identified 40 nonadherent patients (7.3%) using serum drug concentrations. They had higher office diastolic blood pressure (90 versus 83 mm Hg, P<0.01) and daytime diastolic blood pressure (85 versus 80 mm Hg, P<0.01) though systolic blood pressures did not differ significantly. They had more prescribed daily antihypertensive pills (2.5 versus 2.1 pills, P<0.01) and total daily pills (5.5 versus 4.4 pills, P=0.03). Prescription of fixed-dose combination pills were lower among the nonadherent patients identified by serum concentrations (45.0 versus 67.1%, P<0.01). Fifty-three patients self-reported nonadherence, while the investigators suspected 69 nonadherent patients. These groups showed no or few differences in drug regimens, respectively. In summary, we detected 7.3% prevalence of nonadherence by serum drug measurements in patients using ≥2 antihypertensive agents in a nationwide study; they had higher office and ambulatory diastolic blood pressures, higher number of prescribed daily pills, more daily antihypertensive pills, and less frequent prescriptions of fixed-dose combination pills. Indirect methods showed poor overlap with serum drugs concentrations and no or minimal medication differences. Thus, serum measurements of drugs were useful in detection and characterization of nonadherence to antihypertensive treatment.

• Aarskog, Nikolai Ravn; Aass, Hans Christian Dalsbotten; Holter, Jan Cato; Rostrup, Morten & Holten, Aleksander Rygh (2021). Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin? Critical Care Explorations. 3(10). doi: 10.1097/cce.0000000000000542. Full text in Research Archive Show summary

  OBJECTIVES: To examine whether interleukin-6 in critical coronavirus disease 2019 is higher in arterial than in central venous blood, as a sign of predominantly local pulmonal rather than systemic interleukin-6 production. DESIGN: Prospective cohort pilot study with repeated weekly measurements of interleukin-6 in arterial and central venous blood. Respiratory function, assessed with Pao2/Fio2 ratio, was measured at the time of blood sampling. SETTING: ICU at a university hospital. SUBJECTS: Nine adult patients with critical coronavirus disease 2019, actively treated and receiving mechanical ventilation. MEASUREMENTS AND MAIN RESULTS: No difference between arterial and central venous interleukin-6 was found. There was a significant negative relationship between interleukin-6 concentration and P/F ratio in both arterial (p = 0.04) and central venous (p = 0.03) blood. CONCLUSIONS: The absence of an arteriovenous interleukin-6 difference implies that interleukin-6 in critical coronavirus disease 2019 is mainly produced outside the lungs as part of a systemic inflammatory response syndrome and act as a driver of local inflammation and damage in the lungs.

• Olsen, Eirik; Holzhauer, Björn; Julius, Stevo; Kjeldsen, Sverre; Larstorp, Anne Cecilie Kjeldsen & Mancia, Giuseppe [Show all 12 contributors for this article] (2021). Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. Blood Pressure. ISSN 0803-7051. 30. doi: 10.1080/08037051.2020.1856642. Full text in Research Archive Show summary

  Purpose Event-based clinical outcome trials have shown limited evidence to support guidelines recommendations to lower blood pressure (BP) to <130/80 mmHg in middle-aged and elderly hypertensive patients with diabetes mellitus or with general high cardiovascular (CV) risk. We addressed this issue by post-hoc analysing the risk of CV events in patients who participated in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial and compared the hypertensive patients with type 2 diabetes mellitus with all high-risk hypertensive patients. Materials and methods Patients were divided into 4 groups according to the proportion of on-treatment visits before the occurrence of an event (<25% to ≥75%) in which BP was reduced to <140/90 or <130/80 mmHg. Patients with diabetes mellitus (n = 5250) were compared with the entire VALUE population with high CV risk (n = 15,245). Results After adjustments for baseline differences between groups, a reduction in the proportion of visits in which BP was reduced to <140/90 mmHg, but not to <130/80 mmHg, was accompanied by a progressive increase in the risk of CV morbidity and mortality as well as stroke, myocardial infarction and heart failure in both diabetes mellitus and in all high-risk patients. Target BP <130/80 mmHg reduced stroke risk in the main population but not in the diabetes mellitus patients. Patients with diabetes mellitus had higher event rates for the primary cardiac endpoint and all-cause mortality driven by a higher rate of heart failure. Conclusion In the high-risk hypertensive patients of the VALUE trial achieving more frequently BP <140/90 mmHg, but not <130/80 mmHg, showed principally the same protective effect on overall and cause-specific cardiovascular outcomes in patients with diabetes mellitus and in the general high-risk hypertensive population.

• Olsen, Eirik; Holzhauer, Björn; Julius, Stevo; Kjeldsen, Sverre; Larstorp, Anne Cecilie Kjeldsen & Mancia, Giuseppe [Show all 12 contributors for this article] (2021). Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. Blood Pressure. ISSN 0803-7051. doi: 10.1080/08037051.2020.1855968. Full text in Research Archive Show summary

  Purpose Available data of event-based clinical outcomes trials show that little evidence supports the guidelines recommendations to lower blood pressure (BP) to <130/80 mmHg in middle-aged and elderly people with type 2 diabetes mellitus and hypertension. We addressed this issue by post-hoc analysing the risk of cardiovascular (CV) events in mostly elderly high-risk hypertensive patients with type 2 diabetes mellitus participating in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Material and methods Patients (n = 5250) were divided into 4 groups according to the proportion of on-treatment visits before the occurrence of an event (<25% to ≥ 75%) in which BP was reduced to <140/90 or <130/80 mmHg. Results After adjustment for baseline demographic differences between groups, a reduction in the proportion of visits in which BP achieved <140/90 mmHg accompanied a progressive increase in the risk of CV mortality and morbidity as well as of cause-specific events such as stroke, myocardial infarction and heart failure. A progressive reduction in the proportion of visits in which BP was reduced <130/80 mmHg did not have any effect on CV risks. Conclusion In mostly elderly high-risk hypertensive patients with type 2 diabetes mellitus participating in the VALUE trial, achieving more frequently BP <140/90 mmHg showed a marked protective effect on overall and all cause-specific cardiovascular outcomes. This was not the case for a more frequent achievement of the more intensive BP target, i.e. <130/80 mmHg.

• Ernst, Gernot Walter; Watne, Leiv Otto; Frihagen, Frede; Wyller, Torgeir Bruun; Dominik, Andreas & Rostrup, Morten (2021). Low Heart Rate Variability Predicts Stroke and Other Complications in the First Six Postoperative Months After a Hip Fracture Operation. Frontiers in Cardiovascular Medicine. 8, p. 1–8. doi: 10.3389/fcvm.2021.640970. Full text in Research Archive
• Gundem, Trine; Olasveengen, Theresa M.; Hovda, Knut Erik; Gaustad, Knut; Schøndorf, Christina Luise & Rostrup, Morten [Show all 11 contributors for this article] (2020). Ventilasjonsstotte for hypoksemiske intensivpasienter med covid-19. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 140(11), p. 1–10. doi: 10.4045/tidsskr.20.0445. Full text in Research Archive Show summary

  BAKGRUNN Covid-19-pneumoni kan gi alvorlig hypoksemisk respirasjonssvikt som krever intensivmedisinsk behandling. Vi ønsket å beskrive covid-19-intensivpasienter som ble behandlet med og uten invasiv ventilasjonsstøtte. MATERIALE OG METODE Materialet er hentet fra lokalt kvalitetsregister og består av data om pasienter med covid-19 innlagt på intensivavdelingen ved Oslo universitetssykehus, Ullevål i perioden 5.3–28.5.2020. Pasientene ble kategorisert i tre grupper basert på respirasjonssviktbehandlingen (oksygen alene, tillegg av ikke-invasiv ventilasjonsstøtte (NIV) og intubasjon/respirator) og beskrevet med deskriptiv statistikk. RESULTATER Av 165 innlagte covid-19-pasienter ble 26 (16 %) behandlet ved vår intensivavdeling. Fire av disse hadde behandlingsbegrensninger og ble ekskludert. De 22 pasientene inkludert i denne studien hadde gjennomsnittsalder 56 år (spredning 25–78 år), 17 (77 %) var menn. Elleve pasienter fikk respiratorbehandling, syv oksygen på maske og fire tillegg av ikke-invasiv ventilasjonsstøtte. I respiratorgruppen var to døde per 28.5.2020, resten var skrevet ut av intensivavdelingen i live, hvorav én fortsatt lå på sengepost. Alle pasienter behandlet med oksygen og ikke-invasiv ventilasjonsstøtte var i live og utskrevet fra sykehus. FORTOLKNING Mange pasienter med covid-19-respirasjonssvikt og behov for intensivbehandling kan klare seg med økt oksygentilbud og ikke-invasiv ventilasjonsstøtte, men behov for intubasjon må fortløpende vurderes. Over 90 % av aktivt behandlede intensivpasienter overlevde.

• Bergo, Kaja Knudsen; Larstorp, Anne Cecilie Kjeldsen; Hoffmann, Pavel; Hjørnholm, Ulla; Cataliotti, Alessandro & Høieggen, Aud [Show all 8 contributors for this article] (2020). Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood Pressure. ISSN 0803-7051. p. 1–10. doi: 10.1080/08037051.2020.1789446. Full text in Research Archive Show summary

  Purpose Renal sympathetic denervation (RDN) is again gaining interest as recent well-designed trials have demonstrated reduced ambulatory blood pressure (BP) after RDN. However, the hemodynamic mechanisms have not been elucidated. We aimed for the first time to investigate the effect of RDN on the “Hallmark of Hypertension” namely increased systemic vascular resistance index (SVRI). Materials and methods We investigated SVRI change in patients with true treatment-resistant hypertension randomised to RDN (n = 9) or drug adjusted control (n = 9). Treatment-resistant hypertension was defined as office systolic BP ≥ 140 mmHg despite ≥ 3 antihypertensive drugs including a diuretic. True treatment-resistant hypertension was confirmed prior to inclusion with ambulatory daytime systolic BP ≥ 135 mmHg immediately after witnessed intake of antihypertensive drugs. Hemodynamic variables were recorded with thoracic impedance cardiography at baseline and at three and six months follow-up after RDN. This non-invasive method also guided further tailoring of drug treatment in the control group aiming to normalise hemodynamic variables and BP. Results From three to six months follow-up after RDN, SVRI decreased with a median of −611 dyn*s*m2/cm5 [IQR −949 to −267] (p < 0.01), while supine mean BP decreased with a median of −11 mmHg [IQR −21 to −3] (p = 0.02). In the same period, SVRI in the control group was reduced with −674 dyn*s*m2/cm5 [IQR −1,309 to −340] (p < 0.01), while supine mean BP decreased with −15 mmHg [IQR −29 to −6] (p = 0.01). Thus, hemodynamic variables and BP in the two groups normalised in parallel. Conclusion Our data suggest that in patients with true treatment-resistant hypertension, renal sympathetic denervation lowers BP by reducing systemic vascular resistance of similar size as in the control group with careful individual selection of antihypertensive drugs and dose titration.

• Ernst, Gernot; Watne, Leiv; Rostrup, Morten & Neerland, Bjørn Erik (2020). Delirium in patients with hip fracture is associated with increased heart rate variability. Aging Clinical and Experimental Research. ISSN 1594-0667. 32, p. 2311–2318. doi: 10.1007/s40520-019-01447-5. Full text in Research Archive
• Bergland, Ola Undrum; Larstorp, Anne Cecilie Kjeldsen; Søraas, Camilla Lund; Høieggen, Aud; Rostrup, Morten & Kjær, Vibeke Norheim [Show all 9 contributors for this article] (2020). Changes in sympathetic nervous system activity after renal denervation: results from the randomised Oslo RDN study. Blood Pressure. ISSN 0803-7051. p. 1–12. doi: 10.1080/08037051.2020.1868286. Full text in Research Archive Show summary

  Purpose Sympathetic nervous system (SNS) over-activity is associated with essential hypertension. Renal sympathetic denervation (RDN) possibly lowers office- and ambulatory blood pressure (BP) in patients with treatment-resistant hypertension (TRH). We aimed to assess the effect of RDN compared to drug adjustment on SNS activity among patients with TRH by measuring plasma catecholamines and heart rate variability (HRV) during stress tests. Materials and methods Patients with TRH were randomised to RDN (n = 9) or Drug Adjustment (DA) (n = 10). We measured continuous HRV and beat-to-beat-BP using FinaPres® and obtained plasma catecholamines during standardised orthostatic- and cold-pressor stress tests (CPT) before- and six months after randomisation. Results CPT revealed no differences between groups at baseline in peak adrenaline concentration (69.3 pg/mL in the DA group vs. 70.0 pg/mL in the RDN group, p = 0.38) or adrenaline reactivity (Δ23.1 pg/mL in the DA group vs. Δ29.3 pg/mL in the RDN group, p = 0.40). After six months, adrenaline concentrations were statistically different between groups after one minute (66.9 pg/mL in the DA group vs. 55.3 pg/mL in the RDN group, p = 0.03), and six minutes (62.4 pg/mL in the DA group vs. 50.1 pg/mL in the RDN group, p = 0.03). There was a tendency of reduction in adrenaline reactivity after six months in the RDN group (Δ26.3 pg/mL at baseline vs. Δ12.8 pg/ml after six months, p = 0.08), while it increased in the DA group (Δ13.6 pg/mL at baseline vs. Δ19.9 pg/mL after six months, p = 0.53). We also found a difference in the Low Frequency band at baseline following the CPT (667µs2 in the DA group vs. 1628µs2 in the RDN group, p = 0.03) with a clear tendency of reduction in the RDN group to 743µs2 after six months (p = 0.07), compared to no change in the DA group (1052µs2, p = 0.39). Conclusion Our data suggest that RDN reduces SNS activity after six months. This finding warrants investigation in a larger study. Clinical Trial Number registered at www.clinicaltrials.gov: NCT01673516

• Mehlum, Maria Hollund; Liestøl, Knut; Wyller, Torgeir Bruun; Hua, Tsushung A.; Rostrup, Morten & Berge, Eivind (2019). Blood pressure variability in hypertensive patients with atrial fibrillation in the VALUE trial. Blood Pressure. ISSN 0803-7051. 28(2), p. 77–83. doi: 10.1080/08037051.2018.1524707. Full text in Research Archive
• Druce, Philippa; Bogatyreva, Ekaterina; Gates, Scott; Siem, Frederik François; Kaade, Hanna & Sundby, Johanne [Show all 14 contributors for this article] (2019). Approaches to protect and maintain health care services in armed conflict - Meeting SDGs 3 and 16. Conflict and Health. 13:2, p. 1–4. doi: 10.1186/s13031-019-0186-0. Full text in Research Archive Show summary

  The escalation of conflict in the Middle East coincides with an emerging trend of attacks on healthcare. Protection of health personnel, health services and humanitarian workers is no longer respected. This compromises the achievement of the United Nations Sustainable Development Goals 3 – towards health for all, and 16 – towards justice and peace. The Centre for Global Health at the University of Oslo, the Peace Research Institute Oslo and the Norwegian Red Cross co-organised a meeting exploring how conflict impacts health systems and potential solutions to protect and maintain health care services.

• Holen, Øyunn & Rostrup, Morten (2019). Difteriutbrudd i en flyktningleir. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 139(18). doi: 10.4045/tidsskr.19.0488. Full text in Research Archive
• Ernst, Gernot Walter; Watne, Leiv Otto; Frihagen, Frede Jon; Wyller, Torgeir Bruun; Dominik, Andreas & Rostrup, Morten (2017). Decreases in heart rate variability are associated with postoperative complications in hip fracture patients. PLOS ONE. 12:e0180423(7), p. 1–14. doi: 10.1371/journal.pone.0180423. Full text in Research Archive
• Skårn, Sigrid Nordang; Eggesbø, Heidi Beate; Flaa, Arnljot; Kjeldsen, Sverre Erik; Rostrup, Morten & Brunborg, Cathrine [Show all 8 contributors for this article] (2016). Predictors of abdominal adipose tissue compartments: 18-year follow-up of young men with and without family history of diabetes. European journal of internal medicine. ISSN 0953-6205. 29, p. 26–31. doi: 10.1016/j.ejim.2015.11.027. Full text in Research Archive
• Aksnes, Tonje Amb; Kjeldsen, Sverre Erik; Rostrup, Morten; Holzhauer, Björn; Hua, Tsushung A. & Julius, Stevo (2016). Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Blood Pressure. ISSN 0803-7051. 25(4), p. 235–240. doi: 10.3109/08037051.2015.1134071. Full text in Research Archive
• ABOU-ARAB, MOHAMMAD HASSAN; Rostrup, Morten & Heier, Tom (2016). Dose requirements of alfentanil to eliminate autonomic responses during rapid-sequence induction with thiopental 4 mg/kg and rocuronium 0.6 mg/kg. Journal of clinical anesthesia. ISSN 0952-8180. 35, p. 465–474. doi: 10.1016/j.jclinane.2016.09.026. Full text in Research Archive
• Rostrup, Morten; Edwards, Jeffrey K.; Abukalish, Mohamed; Ezzabi, Masoud; Some, David & Ritter, Helga [Show all 13 contributors for this article] (2016). The methanol poisoning outbreaks in Libya 2013 and Kenya 2014. PLOS ONE. 11(3). doi: 10.1371/journal.pone.0152676. Full text in Research Archive
• Skårn, Sigrid Nordang; Flaa, Arnljot; Kjeldsen, Sverre Erik; Rostrup, Morten; Brunborg, Cathrine & Reims, Henrik Mikael [Show all 9 contributors for this article] (2015). Family history of hypertension and serumtriglycerides predict future insulin sensitivity: A17-year follow-up study of youngmen. Journal of Hypertension. ISSN 0263-6352. 33(9), p. 1845–1852. doi: 10.1097/HJH.0000000000000632. Full text in Research Archive
• Elmula, Fadl Elmula M. Fadl; Rebora, Paola; Talvik, Anneli; Salerno, Sabrina; Miszkowska-Nagorna, Eliza & Liu, Xiaoqiu [Show all 17 contributors for this article] (2015). A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients. Journal of Hypertension. ISSN 0263-6352. 33(12), p. 2534–2545. doi: 10.1097/HJH.0000000000000749. Full text in Research Archive
• Tvinnereim, Are Bergsvein; Opdahl, Helge; Rostrup, Morten & Sunde, Kjetil (2015). En ung mann med luftveisinfeksjon og intense smerter. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 135(7), p. 658–661. doi: 10.4045/tidsskr.14.1182. Full text in Research Archive
• Elmula, Fadl Elmula M. Fadl; Rebora, Paola; Talvik, Anneli; Salerno, Sabrina; Miszkowska-Nagórna, Eliza & Liu, Xiaoqiu [Show all 17 contributors for this article] (2015). A randomized and controlled study of noninvasive hemodynamicmonitoring as a guide to drug treatment of uncontrolled hypertensive patients. Journal of Hypertension. ISSN 0263-6352. 33(12), p. 2534–2545. doi: 10.1097/HJH.0000000000000749. Full text in Research Archive
• Skårn, Sigrid Nordang; Flaa, Arnljot; Kjeldsen, Sverre Erik; Rostrup, Morten; Brunborg, Cathrine & Reims, Henrik Mikael [Show all 9 contributors for this article] (2015). High screening blood pressure at young age predicts future masked hypertension: A 17 year follow-up study. Blood Pressure. ISSN 0803-7051. 24(3), p. 131–138. doi: 10.3109/21695717.2015.1030889. Full text in Research Archive
• Sørensen, Heidi; Mula, Fadl El Mula Mohamed Fadl El; Kjeldsen, Sverre Erik; Brekke, Magne; Gjønnæss, Eyvind & Hjørnholm, Ulla [Show all 13 contributors for this article] (2014). Renal sympatisk denervering ved terapiresistent hypertensjon. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 134(1), p. 32–36. doi: 10.4045/tidsskr.13.0276. Full text in Research Archive
• Mula, Fadl El Mula Mohamed Fadl El; HOFFMANN, PAVEL; Larstorp, Anne Cecilie Kjeldsen; Fossum, Eigil; Brekke, Magne & Kjeldsen, Sverre Erik [Show all 13 contributors for this article] (2014). Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. ISSN 0194-911X. 63(5), p. 991–999. doi: 10.1161/HYPERTENSIONAHA.114.03246. Full text in Research Archive
• Mula, Fadl El Mula Mohamed Fadl El; HOFFMANN, PAVEL; Fossum, Eigil; Brekke, Magne; Gjønnæss, Eyvind & Hjørnholm, Ulla [Show all 12 contributors for this article] (2013). Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension After Witnessed Intake of Medication Before Qualifying Ambulatory Blood Pressure. Hypertension. ISSN 0194-911X. 62(3), p. 526–532. doi: 10.1161/HYPERTENSIONAHA.113.01452. Full text in Research Archive
• Hassellund, Skjalg; Flaa, Arnljot; Kjeldsen, Sverre Erik; Seljeflot, Ingebjørg; Karlsen, Anette & Erlund, Iris [Show all 7 contributors for this article] (2013). Effects of anthocyanins on cardiovascular risk factors and inflammation in pre-hypertensive men: a double-blind randomized placebo-controlled crossover study. Journal of Human Hypertension. ISSN 0950-9240. 27(2), p. 100–106. doi: 10.1038/jhh.2012.4. Full text in Research Archive
• Hassellund, Skjalg; Flaa, Arnljot; Sandvik, Leiv; Kjeldsen, Sverre Erik & Rostrup, Morten (2012). Effects of anthocyanins on blood pressure and stress reactivity: a double-blind randomized placebo-controlled crossover study. Journal of Human Hypertension. ISSN 0950-9240. 26(6), p. 396–404. doi: 10.1038/jhh.2011.41. Full text in Research Archive
• Hassellund, Skjalg; Flaa, Arnljot; Kjeldsen, Sverre Erik; Seljeflot, Ingebjørg; Karlsen, Anette & Erlund, Iris [Show all 7 contributors for this article] (2012). Effects of anticyanins on blood pressure, cardiovasclular risk factors and stress reactivity. A double blind randomized placebo-controlled crossover study. Journal of Hypertension. ISSN 0263-6352. doi: 10.1038/jhh.2012.4. Full text in Research Archive
• Hassellund, Skjalg; Flaa, Arnljot; Sandvik, Leiv; Kjeldsen, Sverre Erik & Rostrup, Morten (2010). Cardiovascular (CV) hyper reactivity and increased sympathetic responses to stress. Hypertension. ISSN 0194-911X. 55, p. 131–136. Full text in Research Archive
• Hassellund, Skjalg; Flaa, Arnljot; Sandvik, Leiv; Kjeldsen, Sverre Erik & Rostrup, Morten (2010). Long-Term Stability of Cardiovascular and Catecholamine Responses to Stress Tests An 18-Year Follow-Up Study. Hypertension. ISSN 0194-911X. 55(1), p. 131–136. doi: 10.1161/HYPERTENSIONAHA.109.143164. Full text in Research Archive
• Rostrup, Morten (2008). Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study. Metabolism: Clinical and Experimental. ISSN 0026-0495. Full text in Research Archive
• Flaa, Arnljot; Ekeberg, Øivind; Kjeldsen, Sverre Erik & Rostrup, Morten (2007). Personality may influence reactivity to stress. BioPsychoSocial Medicine. 1(5). doi: 10.1186/1751-0759-1-5. Full text in Research Archive Show summary

  Background: Possible mechanisms behind psychophysiological hyperreactivity may be located at a cognitive-emotional level. Several personality traits have been associated with increased cardiovascular reactivity. Subjects with white coat hypertension, which may constitute a kind of hyperreactivity, are found to suppress their emotions and adapt to the surroundings to a larger extent than controls. We hypothesized in this study that a) stress reactivity is related to personality, and that b) responses to cold pressor test (CPT) and mental stress test (MST) are associated with different personality traits. Methods: 87 men were selected from the 1st, 50th and 99th percentile of a blood pressure screening. Cardiovascular and catecholamine responses to MST and CPT were recorded. Fifteen personality traits were assessed using the Karolinska Scale of Personality. Possible independent explanatory predictors for cardiovascular and catecholamine variables at baseline and during stress were analyzed in multiple linear regression analyses using a stepwise forward procedure. Results: Multiple regression analyses showed that muscular tension (β = 0.298, p = 0.004), irritability (β = 0.282, p = 0.016), detachment (β = 0.272, p = 0.017), psychasthenia (β = 0.234, p = 0.031) and somatic anxiety (β = 0.225, p = 0.046) were significant explanatory variables of reactivity to CPT. During MST, verbal aggression (β = -0.252, 0.031) and detachment (β = 0.253, p = 0.044) were significant predictors of norepinephrine and diastolic blood pressure response, respectively. Based on KSP-trait quartiles, delta (Δ) systolic (p = 0.025) and Δ diastolic blood pressure (p = 0.003) during MST were related to detachment score, with the highest reactivity in the 4th quartile, while Δ norepinephrine was significantly related to muscular tension (p = 0.033). Δ systolic and Δ diastolic blood pressure responses to CPT were dependent on detachment (p = 0.049 and p = 0.011, respectively) and psychasthenia (p = 0.020 and p = 0.015), while high verbal aggression was associated with lower reactivity measured by Δ norepinephrine (p = 0.037). Conclusion: The present study indicates that stress reactivity is clearly related to different personality traits, without any single trait being dominant over others. Furthermore, personality seems to have as much, or even more, importance of predicting responses to CPT than responses to MST

• Myre, Kirsti; Rostrup, Morten; Eriksen, Morten; Buanes, Trond; Ræder, Johan & Stokland, Olav Audun (2004). Increased spillover of norepinephrine to the portal vein during CO2-pneumoperitoneum in pigs. Acta Anaesthesiologica Scandinavica. ISSN 0001-5172. 48, p. 443–450. Full text in Research Archive

View all works in NVA

• Olsen, Erik; Søraas, Camilla Lund; Mariampillai, Julian Eek; Kjeldsen, Sverre; Larstorp, Anne Cecilie Kjeldsen & Rostrup, Morten (2025). Insights from the VALUE Trial: Achieving blood pressure targets for renal protection. European journal of internal medicine. ISSN 0953-6205. doi: 10.1016/j.ejim.2025.05.010. Full text in Research Archive
• Aarskog, Nikolai Ravn; Iuell, Ragnhild Skari; Dunlop, Oona Borghild; Sevre, Knut; Bendz, Bjørn & Rostrup, Morten (2023). Neuropsychological function is associated with hypocapnia at simulated high altitude. Acta Physiologica. ISSN 1748-1708. doi: 10.1111/apha.13949. Full text in Research Archive
• Halvorsen, Lene Vernås; Gognstad, Stine; Søraas, Camilla Lund; Ågnes, Camilla; Hjørnholm, Ulla & Kjær, Vibeke Norheim [Show all 21 contributors for this article] (2022). Implications of CYP2D6 polymorphisms for therapeutic drug monitoring in patients with hypertension. Journal of Hypertension. ISSN 0263-6352. 40, p. e310–e310. doi: 10.1097/01.hjh.0000838764.61491.a8. Full text in Research Archive
• Gundem, Trine; Olasveengen, Theresa M.; Schøndorf, Christina Luise; Hovda, Knut Erik; Rostrup, Morten & Frøyshov, Sten [Show all 11 contributors for this article] (2020). T.M. Gundem og medarbeidere svarer. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 140(12), p. 1–2. doi: 10.4045/tidsskr.20.0650. Full text in Research Archive
• Kjeldsen, Sverre Erik; Sørensen, Heidi; Mula, Fadl El Mula Mohamed Fadl El; Brekke, Magne; Gjønnæss, Eyvind & Hjørnholm, Ulla [Show all 13 contributors for this article] (2014). Re: Renal sympatisk denervering ved terapiresistent hypertensjon. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 134(15), p. 1449–1450. Full text in Research Archive
• Hassellund, Skjalg; Flaa, Arnljot; Kjeldsen, Sverre Erik & Rostrup, Morten (2010). NO EFFECT OF CONCENTRATED ANTHOCYANINS WITH HIGH ANTI-OXIDANT PROPERTIES ON BP IN PATIENTS WITH MILD HYPERTENSION; A RANDOMIZED PLACEBO-CONTROLLED CROSS-OVER STUDY. Journal of Hypertension. ISSN 0263-6352. 28, p. E119–E119. Full text in Research Archive
• Aksnes, Tonje Amb; Rostrup, Morten; Kjeldsen, Sverre Erik; Holzhauer, Bjoern; Hua, Tsushung A. & Julius, Stevo (2010). PREDICTORS OF CARDIAC MORBIDITY IN DIABETIC, NEW-ONSET DIABETIC AND NON-DIABETIC HIGH-RISK HYPERTENSIVE PATIENTS: THE VALUE TRIAL. Journal of Hypertension. ISSN 0263-6352. 28, p. E219–E220. Full text in Research Archive
• Ernst, Gernot Walter & Rostrup, Morten (2010). HEART RATE VARIABILITY IN PALLIATIVE PATIENTS - A PILOT STUDY. Journal of Hypertension. ISSN 0263-6352. 28, p. E467–E467. Full text in Research Archive
• Bekken, Anette Skei; Öjlert, Åsa Kristina; Bjørnaas, Mari Asphjell; Rostrup, Morten; Haldorsen, Tor & Jacobsen, Dag [Show all 7 contributors for this article] (2005). Mortality and causes of death among opiod addicts in Oslo: A 20-year follow-up study. Full text in Research Archive
• Myre, Kirsti; Eriksen, M.; Ræder, Johan; Rostrup, Morten; Buanes, Trond & Stokland, Olav Audun (2004). Increased spillover of norepinephrine to the portal vein during CO2-pneumoperitoneum in pigs. Universitetet i Oslo. Full text in Research Archive

View all works in NVA